Pathology: locally advanced NSCLC - (neo)adjuvant (NA); mNSCLC - L1 - PDL1 negative; mNSCLC - L1 - PDL1 positive; mNSCLC - L2 - all population; non squamous - mNSCLC - L2 - all population; NSCLC neoadjuvant setting; squamous - mNSCLC - L2 - all population;
locally advanced NSCLC - (neo)adjuvant (NA) | mNSCLC - L1 - PDL1 negative | mNSCLC - L1 - PDL1 positive | mNSCLC - L2 - all population | non squamous - mNSCLC - L2 - all population | NSCLC neoadjuvant setting | squamous - mNSCLC - L2 - all population | |||
CheckMate 816, 2022 | CheckMate 227 (NC vs C ; PDL1<1%), 2018 | CheckMate 026 (PDL1>1%), 2016 | CheckMate 026 (PDL1>5%), 2016 | CheckMate 078, 2019 | CheckMate 057, 2015 | CheckMate 816, 2022 | CheckMate 017, 2015 | ||
nivolumab alone | 5 | T1 | T1 | T1 | T1 | T1 | |||
nivolumab plus SoC | 3 | T1 | T1 | T1 | |||||
placebo plus SoC | 0 | T0 | T0 | ||||||
pemetrexed plus platin | 0 | T0 | |||||||
Standard of Care (SoC) | 0 | T0 | T0 | ||||||
docetaxel | 0 | T0 | T0 | T0 |